The Role of Oxytocin in the Perception of Faces

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

71 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this project is to study whether intranasal oxytocin (OT) affects how young adults perceive and attend to infant and adult faces. Based on existing research the investigators predict that oxytocin will facilitate the allocation of attentional resources on infant faces (compared to adult faces). The investigators also predict that oxytocin will enhance the activity of reward neural-networks associated with the perception of infant faces. The behavioral effects of OT (visual attention and face recognition) will be measured with eye-tracking while participants look at photographs of adult and infant faces. Neurological effects (the activity of emotion and reward networks) will be measured with functional Magnetic Resonance Imaging (fMRI) while participants look at infant faces on a computer screen.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inhaled Oxytocin and HPA Axis Reactivity

NCT03593473

Depression, Postpartum Anxiety Disorders Stress, Psychological

COMPLETED PHASE2

Intranasal Oxytocin and Maternal Neglect

NCT02737436

Maternal Behavior

COMPLETED NA

Oral Oxytocin Modulation of Responses to Emotional Stimuli

NCT04320706

Healthy

UNKNOWN NA

Oxytocin Modulation of Startle Reactivity to Social Stimuli and Moral Decision Making

NCT01607970

Healthy Male Volunteers

COMPLETED PHASE1

Prenatal Cocaine, Nasal Oxytocin, and Maternal Psychophysiology

NCT02872467

Substance Abuse Problem Pregnancy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intranasal oxytocin group

Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).

Group Type EXPERIMENTAL

Syntocinon (synthetic oxytocin)

Intervention Type DRUG

Dosage and details described in arm.

Placebo group

The placebo is identical to the oxytocin formulation with the exception of the active compound.

Participants will self-administer three puffs per nostril of placebo (6 puffs total).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Dosage and details described in arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Syntocinon (synthetic oxytocin)

Dosage and details described in arm.

Intervention Type DRUG

Placebo

Dosage and details described in arm.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Volunteers
* Norma or corrected to norma vision
* Participants are non parents
* Able to provide written informed consent and to comply with all study procedures

Exclusion Criteria

* Dementia or severe cognitive disorders
* Endocrine disease or malignancy
* Nasal obstruction or upper-respiratory tract infection
* Current or previous psychiatric disorder
* Current or previous use of psychoactive drugs
* Alcoholism or substance abuse
* History of seizures
* Neurological Disorder
* Previous head trauma
* Hypertension
* Cardiovascular Disease
* Claustrophobia
* ferrous metal in any part of the body

Minimum Eligible Age

18 Years

Maximum Eligible Age

25 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes